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Abstract
Oxidative reactions that are catalyzed by cytochromes P450 1A (CYP1A) lead to formation
of carcinogenic derivatives of arylamines and polycyclic aromatic hydrocarbons (PAHs), such
as the widespread environmental pollutant benzo(α)pyrene (BP). These compounds upregu-
late CYP1A at the transcriptional level via an arylhydrocarbon receptor (AhR)-dependent sig-
naling pathway. Because of the involvement of AhR-dependent genes in chemically induced
carcinogenesis, suppression of this signaling pathway could prevent tumor formation and/or
progression. Here we show that menadione (a water-soluble analog of vitamin K3) inhibits
BP-induced expression and enzymatic activity of both CYP1A1 and CYP1A2 in vivo (in the
rat liver) and BP-induced activity of CYP1A1 in vitro. Coadministration of BP and menadione
reduced DNA-binding activity of AhR and increased DNA-binding activity of transcription fac-
tors Oct-1 and CCAAT/enhancer binding protein (C/EBP), which are known to be involved in
negative regulation of AhR-dependent genes, in vivo. Expression of another factor involved in
downregulation of CYP1A—pAhR repressor (AhRR)—was lower in the liver of the rats
treated with BP and menadione, indicating that the inhibitory effect of menadione on CYP1A
is not mediated by this protein. Furthermore, menadione was well tolerated by the animals: no
signs of acute toxicity were detected by visual examination or by assessment of weight gain
dynamics or liver function. Taken together, our results suggest that menadione can be used
in further studies on animal models of chemically induced carcinogenesis because menadi-
one may suppress tumor formation and possibly progression.
Introduction
Cytochromes P450 of the 1A subfamily (CYP1A1 and CYP1A2) metabolize most common
environmental pollutants: polycyclic aromatic hydrocarbons (PAHs) (such as benzo(α)pyrene
(BP), BP-like compounds) and arylamines. These enzymes catalyze all reactions of PAH
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biotransformation including the ones generating highly reactive molecules that exert carcino-
genic and mutagenic effects on the cells [1, 2].
PAHs induce CYP1A expression via a ligand-activated transcription factor aryl hydrocar-
bon receptor (AhR) belonging to the family of bHLH/PAS (basic helix-loop-helix/Per-ARNT--
Sim) transcription factors. Inactive AhR is located in the cytoplasm, in complex with other
proteins. Ligand-bound AhR moves to the nucleus and dimerizes with Ah receptor nuclear
translocator (ARNT). The resulting heterodimer binds to xenobiotic responsive elements
(XREs) in the enhancers of AhR-dependent genes and enhances their transcription [2].
Negative regulation of CYP1A has been studied less thoroughly. CYP1A suppression can be
mediated by AhR repressor (AhRR), which competes with AhR for binding to ARNT and
forms the heterodimer AhRR–ARNT; the latter binds to XRE but fails to upregulate gene
expression. In addition, transcription factors Oct-1 and C/EBPβ, whose binding sites are
located in the upstream region of the CYP1A1 gene, can repress expression of CYP1A1 inde-
pendently of AhR [3, 4].
For a long time, the only known inducers of CYP1A have been PAH-like compounds [5]. In
the last decades, however, numerous structurally diverse compounds were discovered that
weakly or moderately activate CYP1A: flavonoids, indoles [6, 7], and synthetic retinoids [8],
benzimidazole drugs [9], quercetin, resveratrol, and curcumin [10]. Some of them were shown
to bind to AhR [6–8]. Other compounds may activate AhR-dependent signaling and CYP1A
expression indirectly [9, 10].
Many of these weak inducers can suppress PAH-induced activation of CYP1A [11–16] by
different mechanisms, for instance, competition for the active center of AhR [12], inhibition of
phosphorylation of AhR and/or ARNT [17], or activation of transcriptional suppressors of
CYP1A1 [4]. In many cases, however, molecular mechanisms of downregulation of PAH-
induced CYP1A1 activity by weak inducers have yet to be elucidated.
Because most if not all negative effects of PAHs are mediated by AhR and AhR-dependent
genes [18], the suppression of AhR activity and downregulation of its target genes may be used
to reduce the adverse effects of PAHs and to control chemically induced carcinogenesis.
Indeed, experimental animals lacking AhR or CYP1A1 were shown to be resistant to the toxic
and carcinogenic effects of classical AhR ligands [19–22]. In addition, many of the substances
interfering with the action of “classic” CYP1A inducers have anticarcinogenic properties [23–
25]. Nevertheless, an insufficient understanding of molecular mechanisms underlying this
interference limits the clinical use of such substances. Thus, identification of novel molecules
suppressing the PAH-induced CYP1A activation and elucidation of the negative regulation of
CYP1Amay facilitate the development of novel compounds that prevent tumor formation.
Previously we have shown that menadione (vitamin K3, 2-methyl-1,4-naphthoquinone) is a
weak inducer of CYP1A in experimental animals [26]. The aims of the present study were to
evaluate the effects of menadione on BP-induced activity of CYP1A in vitro and in vivo and to
identify the underlying molecular mechanisms. We found that menadione inhibits CYP1A1
activity in vitro by a noncompetitive mechanism. In vivo, menadione suppressed BP-induced
CYP1A activation at the transcriptional level. This effect was accompanied by a decrease in the
binding of AhR-ARNT to XRE and by an increase in DNA-binding activities of Oct-1 and C/
EBP.
Materials and Methods
Reagents
Acrylamide, tris(hydroxymethyl)aminomethane, NADPH, ammonium persulfate, bovine
serum albumin, ethyleneglycoltetraacetic acid (EGTA), poly[dI-dC], spermidine, dithiothreitol
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(DTT), phenylmethanesulfonylfluoride (PMSF), naphthol AS-MX phosphate, Fast Red Salt,
Ponceau S, an anti-mouse biotinylated antibody, ExtrAvidin-Alkaline Phosphatase, and mena-
dione were purchased from Sigma−Aldrich (USA); Protan Nitrocellulose Transfer Membrane
from Schleicher & Schuell (Germany); spermine from ICN (USA); ammonium sulfate from
Helicon (Russia); caproic acid from AppliChem (Germany); N,N0-methylenebisacrylamide,
sodium dodecyl sulfate (SDS), dimethyl sulfoxide (DMSO), HEPES, and TEMED from Serva
GmbH (Germany); 2-mercaptoethanol and Tween 20 from Ferak Berlin (Germany); MgCl2
from Janssen Chimica (Belgium); glycine and ethylenediaminetetraacetic acid (EDTA) from
Merck (Germany); the TRI-Reagent and RNAsecure Reagent from Ambion, Inc. (USA);
7-ethoxyresorufin, 7-methoxyresorufin, M-MuLV reverse transcriptase, and RNasin from Pro-
mega Corporation (USA); the PCR kit qPCRmix-HS from Evrogen (Russia); glycerol from
Panreac Quimica S.A.U. (Spain); α32P-ATP from Amersham Pharmacia Biotech (USA); Kle-
now enzyme and sucrose fromMedigen (Russia); oligonucleotides (primers) for analysis of the
rat genes Cyp1a1, Cyp1a2, AhR, AhRR, ARNT, and Gapdh as well as XRE3, NRE (negative reg-
ulatory element), C/EBP, and random hexanucleotide primers were from Syntol (Russia) or
Medigen (Russia). All other chemicals were of analytical grade.
Animals
Experiments were performed on male Wistar rats (weighing 100–200 g) from the stock main-
tained at the Animal Facility of the Institute of Cytology and Genetics, SB RAS, (Novosibirsk,
Russia). The use of the experimental animals and experimental procedures were approved by
the Animal Care Committee of the Institute of Molecular Biology and Biophysics, SB RAMS
(Novosibirsk, Russia). The number of animals per group was estimated on the basis of the data
from a pilot experiment to achieve statistical power of 0.8. The animals were housed in plastic
cages in groups of five under standard conditions (12:12 h light/dark regimen; food and water
available ad libitum). The compounds to be administered were dissolved in vegetable oil. The
rats were injected with BP intraperitoneally (25 mg/[kg body weight]) once a day for three
days, or received menadione (15 mg/kg) for four days per os, or received both BP (25 mg/kg)
for three days and menadione (15 mg/kg) for four days. The control group received vegetable
oil. The dose and duration of menadione administration were chosen on the basis of our previ-
ous data [27] to achieve a maximal effect on CYP1A enzymes. All rats were examined and
weighed daily. No signs of toxicity or pain were observed in the treatment groups. The rats
were anesthetized with ethyl ether and decapitated 24 h after the last administration of
menadione.
Preparation of rat liver microsomes
Rat liver microsomes were prepared by differential ultracentrifugation [28]. The livers were
transcardially perfused with a cold buffer consisting of 1.15% KCl and 20 mM Tris-HCl (pH
7.4), dissected, and homogenized in the same buffer. Liver homogenates were centrifuged for
20 min at 10,000 × g, and the resulting supernatants were centrifuged for 60 min at 105,000 ×
g. The final pellets were resuspended in 0.1 M KH2PO4 buffer (pH 7.4) containing 20% of glyc-
erol. Protein concentrations were measured by the Lowry method [29], with bovine serum
albumin as a standard.
Assays of enzymatic activity
Selective activities of the CYP1A isoforms 7-ethoxyresorufin-O-deethylase (CYP1A1) and
7-methoxyresorufin-O-demethylase (CYP1A2) were measured by the spectrofluorimetric
method described by Burke and colleagues [28].
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NADPH reductase activity was measured spectrophotometrically with cytochrome c as a
substrate [30]. Glutathione S-transferase (GST) activity was quantified spectrophotometrically
with 2,4-dinitrochlorobenzene as a substrate as described by Habig [31]. Alanine transaminase
(ALT) and aspartate transaminase (AST) activities were measured on an AU480 Chemistry
System (Beckman Coulter, USA) by the kinetic method according to the manufacturer’s
instruction manual.
The malondialdehyde (MDA) assay
The level of MDA was measured by the method based on the reaction with the thiobarbituric
acid described by Andreeva [32]. Briefly, 200 μL of hepatic microsomes was mixed with 500 μL
of 50 mM Tris-HCl (pH 7.2) and 500 μL of 15% trichloroacetic acid. The resulting mixture was
centrifuged at 1500 × g for 10 min. The supernatant was collected and mixed with 0.75% thio-
barbituric acid (1:1), and these samples were incubated in a water bath at 100°C for 15 min,
then placed on ice for 5 min, and centrifuged at 1000 × g for 10 min. After that, absorbance at
532 nm (A532) of the resulting supernatant was measured, with 580 nm as the reference wave-
length (used for baseline correction). MDA quantity was calculated as C(MDA) = (A532 − A580)
K, where K is a millimolar extinction coefficient equal to 155 mM−1 cm−1.
RNA isolation, reverse transcription, and real-time PCR
Total RNA was isolated using the TRI-Reagent kit (Ambion). The RNA pellets were dissolved
in 1 mM sodium citrate buffer (pH 6.5) containing 1× RNAsecure Reagent (Ambion). Con-
taminating DNA was digested with RNase-free DNase (Promega, USA) under the following
conditions: 3 μg of total RNA, 3 units (U) of RQ1 RNase-free DNase, reaction buffer (40 mM
Tris-HCl pH 8.0, 10 mMMgSO4, and 1 mM CaCl2), and 20 U of RNasin. Reverse transcription
was performed using M-MLV Reverse Transcriptase (Promega, USA). The reaction mixture
(25 μL) contained 500 ng of total RNA, reaction buffer (50 mM Tris-HCl pH 8.3, 75 mM KCl,
3 mMMgCl2, and 10 mMDTT), 1 mM dNTPs, 200 U of M-MuLV reverse transcriptase, 4 μg
of random hexamer primers, and 25 U of RNasin.
The sequences of PCR primers are presented in Table 1. Gapdh was used as a reference
gene. The gene expression was evaluated on an iCycler CFX96 real-time PCR detection system
(Bio-Rad Laboratories, USA) according to the TaqMan principle. The reaction mixture con-
tained the qPCRmix-HS buffer (Evrogen, Russia), 100 nM probe, 400 nM of the forward and
reverse primers, and 1000 ng of cDNA. The reaction was carried out under the following con-
ditions: initial denaturation at 95°C for 3 min, then 40 cycles of denaturation at 95°C for 15 s
and annealing/extension at 60°C for 30 s. All the samples were analyzed in triplicate in two
independent experiments. Relative cDNA levels of the genes under study and of the reference
gene were calculated in the iCycler CFX96 real-time PCR software on the basis of standard
curves built for each experiment with serial dilutions (1:3 to 1:27) of a cDNA standard (pre-
pared by mixing cDNA from all samples) [33, 34]. For each sample, the amount of cDNA of a
gene in question was normalized to the reference gene.
Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting
SDS-PAGE was carried out according to the Laemmli method [35]. For detection of CYP1A,
0.5 μg of microsomal proteins (from rats treated with either BP or BP and menadione) or 80 μg
of protein (from control rats) was loaded onto each lane of a 10% polyacrylamide gel, separated
at 20 mA, and transferred to a nitrocellulose membrane by means of Fastblot B34 (Biometra,
Germany). Efficiency of the transfer was confirmed by Ponceau S staining. The membrane was
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blocked in 5% nonfat dry milk in 1× TBS buffer (20 mM Tris-HCl pH 7.5, 150 mMNaCl) con-
taining 0.05% Tween 20 (TBS-T), overnight at 4°C, and was then incubated for 1 h at 37°C on
a shaker. The membrane was washed three times with TBS-T and was then incubated with
antibodies against rat CYP1A1 and CYP1A2 [36] for 1.5 h at room temperature. After that, the
membrane was washed three times with TBS-T and incubated with an alkaline phosphatase-
conjugated secondary antibody for 1 h. The membranes were washed three times with TBS-T.
The bound antibodies were visualized using naphthol AS-MX phosphate and Fast Red Salt.
Preparation of nuclear protein extracts
Nuclear extracts from the liver of the experimental animals were prepared according to the
method of Gorski and coauthors [37] with modifications described by Shapiro et al. [38].
Briefly, the livers were transcardially perfused with the buffer consisting of 1.15% KCl and 20
mM Tris-HCl pH 7.4, cut into fragments, and homogenized in sucrose buffer (10 mMHEPES
pH 7.6, 25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2.05 M sucrose,
and 10% glycerol). The homogenates were layered on top of 5 mL of sucrose buffer and centri-
fuged in a SW28 rotor (Optima L-90K Ultracentrifuge, Beckman Coulter, USA) at 24,000 rpm
for 40 min. The pelleted nuclei were resuspended in 4 mL of lysis buffer (10 mMHEPES pH
7.6, 100 mM KCl, 3 mMMgCl2, 0.3 M EDTA, 1 mM DTT, 10% glycerol, and 0.1 mM PMSF)
and lysed by the addition of 0.4 mL of a supersaturated (NH4)2SO4 solution. Chromatin was
precipitated by centrifugation in the SW65 rotor at 38,600 rpm for 90 min. Nuclear proteins
were precipitated by (NH4)2SO4 (0.252 g per milliliter of the protein solution) and collected by
centrifugation in the SW65 rotor at 36,200 rpm for 20 min. The resulting pellets were dissolved
in 0.2–0.5 mL of dialysis buffer (25 mMHEPES pH 7.6, 80 mM KCl, 0.1 mM EDTA, 0.2 mM
EGTA, 1 mMDTT, 10% glycerol, and 0.1 mM PMSF). The nuclear extracts were dialyzed
against 100 volumes of the buffer three times for 30–45 min each, split into aliquots, and stored
at −70°C. Protein concentration was determined by the Bradford method [39]. Bovine serum
albumin served as a standard.
Table 1. Primer sequences for analysis of gene expression.
Gene Sequence
Cyp1a1 Forward 50-CCAAACGAGTTCCGGCCT-30
Cyp1a1 Reverse 50-TGCCCAAACCAAAGAGAATGA-30
Cyp1a1 Probe 50(FAM)-TTCTCACTCAGGTGTTTGTCCAGAGTGCC-(BHQ1)30
Cyp1a2 Forward 50-CGCCCAGAGCGGTTTCTTA-30
Cyp1a2 Reverse 50-TCCCAAGCCGAAGAGCATC-30
Cyp1a2 Probe 50(FAM)-CAATGACAACACGGCCATCGACAAG-(BHQ1)30
AhR Forward 50-TGGACAAACTCTCCGTTCTAAGG-30
AhR Reverse 50-GATTTTAATGCAACATCAAAGAAGCT-30
AhR Probe 50(FAM)-CAGCGTCACGTACCTGAGGGCCA-(BHQ1)30
ARNT Forward 50-TGGACCCTGTTTCCATGAATAG-30
ARNT Reverse 50-TGCAGTGGACTACCACAAAG-30
ARNT Probe 50(FAM)-FAM-ATGCAGGAATGGACTTGGCTCTGT-(BHQ1)30
AhRR Forward 50-CAGTGCTGCCTTCTGTGACTGA-30
AhRR Reverse 50-CTCCATTGCTCCTTCCTGCTAA-30
AhRR Probe 50(FAM)-TTCTTGAAGGCAAAGCACACAGGGCAGAC-(BHQ1)30
Gapdh Forward 50-CAAGGTCATCCATGACAACTTTG-30
Gapdh Reverse 50-GGGCCATCCACAGTCTTCTG-30
Gapdh Probe 50(FAM)-ACCACAGTCCATGCCATCACTGCCA-(BHQ1)30
doi:10.1371/journal.pone.0155135.t001
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The electrophoretic mobility shift assay (EMSA)
To assess the binding of nuclear proteins to the specific DNA sequences, we used the following
oligonucleotides: for XRE3 sequences, forward 50-TGCACGGAGTTGCGTGAGAAGAGCCA
TGCA-30 and reverse 30-ACGTgcctcaacgcactcttctcggtACGT-50 [40]; for C/EBP consensus
sequences, forward 50-TGCAGATTGCGCAATCTGCA-30 and reverse 30-ACGTCTAACGCG
TTAGACGT-50 [41]; for C/EBP mutant sequences, forward 50-TGCAGAGACTAGTCTCTG
CA-30 and reverse 30-ACGTCTCTGATCAGAGACGT-50 [41]; for Oct-1 consensus sequences,
forward 50-TGCATGTCGAATGCAAATCACTAGAATGCA-30 and reverse 30-ACGTACAG
CTTACGTTTAGTGATCTTACGT-50 [42]; and for Oct-1 mutant sequences, forward 50-TGC
ATGTCGAATGCAAGCCACTAGAATGCA-30 and reverse 30-ACGTACAGCTTACGTTCG
GTGATCTTACGT-50 [42]. The oligonucleotides were radioactively labeled using a standard
protocol [43]. Briefly, 20 pmol of oligonucleotides for XRE3 sequences were incubated with
20 μCi of α32P-dATP and 2 U of Klenow polymerase in a buffer consisting of 50 mM Tris-HCl
pH 7.6, 10 mMMgCl2, and 5 mMDTT. The oligonucleotides were purified from unbound
α32P-dATP on G-50 spin columns or DEAE filters. Nucleoprotein complexes were formed
under the following conditions: 1× DNA binding buffer (25 mMHEPES pH 7.6, 80 mM KCl,
0.1 mM EDTA, 1 mMDTT, 10% glycerol, 4–5 μg of protein of nuclear extracts [depending on
the oligonucleotide being tested], 0.83 μg of salmon sperm DNA, and a 32P-labeled DNA probe
[400–1000 cpm/reaction]). All components of the reaction mixture except for the labeled oligo-
nucleotide were mixed in a total volume of 11 μL and preincubated on ice for 10 min to block
nonspecific binding. After that, a 32P-labeled DNA probe was added, and the samples were
incubated at room temperature for 10 min. To assess specificity of the DNA-protein com-
plexes, either mutant oligonucleotides were used or a 20-, 50-, or 75-fold excess of an unlabeled
oligonucleotide was added to the reaction mixture. The resulting DNA-protein complexes
were analyzed by electrophoresis in a 4% nondenaturing polyacrylamide gel in 0.5× TBE buffer
(44.5 mM Tris base, 44.5 mM boric acid, and 1 mM EDTA). After the electrophoresis, the gel
was dried, and the DNA-protein complexes were visualized by autoradiography. Each experi-
ment was repeated twice with samples from three rats.
In vitro evaluation of menadione’s effects on CYP1A1 activity
Immediately before measurement of the CYP1A1 activity, menadione was added to the micro-
somes at a final concentration 0.977, 1.955, 4.614, 7.775, 9.775, 14.662, 19.549, 24.44, or
29.324 μM. Each concentration of menadione was analyzed three times. The inhibition con-
stant (Ki) was determined by the graphical method as modulus of the value of inhibitor con-
centration at the point of intersection of the X-axis and a plot of 1/(reaction rate) versus 1/
(substrate concentration) in the presence of different menadione concentrations [44]. To
ensure correct calculation of the reaction rate, the remaining 7-ethoxyresorufin-O-deethylase
(EROD) activity in the liver microsomes was tested once every six measurements. To deter-
mine the type of inhibition, we used the graphical method in which 1/(rate of reaction) was
plotted against 1/(ethoxyresorufin concentration) in the absence or presence of different con-
centrations of menadione [44]. The appearance of the plot indicated a noncompetitive mecha-
nism of inhibition of CYP1A1 activity by menadione in vitro.
Statistical analysis
All calculations were performed in the Statistica software package (StatSoft, Inc., USA). Differ-
ences between groups were assessed by Student’s t test, the Mann–Whitney rank sum test, or
analysis of variance (ANOVA) with the Newman–Keuls post hoc test.
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Results
The effect of menadione on BP-induced CYP1A1 activity in vitro
To study the effect of menadione on BP-induced CYP1A1 activity in vitro, we added various
concentrations of menadione to the hepatic microsomes of rats treated with BP. The results are
shown in Fig 1. Addition of 1–29 μMmenadione to the hepatic microsomes of BP-treated rats
caused a dose-dependent decrease of CYP1A1 activity (Fig 1A). Menadione inhibited the
CYP1A1 in vitro noncompetitively, with Ki = 3.24 μM (determined graphically; Fig 1B).
Activities of hepatic enzymes, weight gain, and lipid peroxidation in rats
treated with BP or BP and menadione
We previously demonstrated that menadione is a weak transcriptional inducer of CYP1A [26].
In the present study, we administered a combination of BP and menadione to rats to determine
the effect of coadministration of a weak CYP1A inducer and a strong one. In line with results
of other studies [4, 11–13], there was a significant increase in CYP1A1/2 activity in the liver of
the rats treated with menadione or BP (Fig 2A–2D). Coadministration of BP and menadione
caused an approximately twofold decrease in CYP1A1/2 activity (Fig 2B and 2D) in compari-
son with the rats injected with BP alone.
Activity of another enzyme that is partly controlled by AhR [45]—glutathione S-transferase
(GST)—was also reduced in the liver of the rats treated with both BP and menadione, as com-
pared to the rats treated with BP alone (S1 Fig). At the same time, menadione affected neither
NADPH reductase (a key enzyme in the electron transfer chain; S2 Fig) nor lipid peroxidation,
judging by the results of MDA quantification (S3 Fig).
No signs of general toxicity or acute adverse effects were detected in the treatment groups.
The weight of the experimental animals remained unchanged during the study period (S4A
Fig). Menadione administration did not alter liver function either: activity of the liver enzyme
ALT in the serum of rats treated with menadione or both BP and menadione remained the
same as that in control animals (S4B Fig); activity of AST increased in response to BP by 28%,
and a similar change was seen in the group treated with both BP and menadione (S4C Fig).
Taken together, these results indicate that the observed reduction in BP-induced CYP1A
activities may be caused by a decrease in the CYP1AmRNA level (as a result of either transcrip-
tional downregulation or mRNA destabilization) and is not due to disruption of the electron
transfer chain, oxidative damage to the enzyme, liver damage, or acute toxicity.
Fig 1. Menadione inhibits CYP1A1 activity in vitro via a noncompetitive mechanism. (A) Menadione
inhibits CYP1A1 activity in vitro in the hepatic microsomes of benzo(α)pyrene-treated rats by a (B)
noncompetitive mechanism with Ki = 3.24 μM. All measurements were performed in duplicate in three
independent experiments. CYP1A1 activity was measured by means of the rate of O-dealkylation of
ethoxyresorufin as described by Burke and colleagues [28].
doi:10.1371/journal.pone.0155135.g001
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Fig 2. Menadione inhibits benzo(α)pyrene (BP)-induced CYP1A activity in vivo via a transcriptional
mechanism. (A, C) Administration of menadione increases activity of CYP1A1 and CYP1A2. (B, D)
Coadministration of BP and menadione suppresses activity of CYP1A1 and CYP1A2 and (E) their protein
and (F, G) mRNA expression that was induced by BP. Rats received BP at 25 mg/(kg body weight) once a
day for three days, menadione (15 mg/kg for four days), or both BP (25 mg/[kg body weight] for three days)
and menadione (15 mg/kg for four days). The control group received vegetable oil. The data are presented as
mean ± SEM (n = 4 to 8); *p < 0.05 according to ANOVA with the Newman–Keuls post hoc test, #p < 0.05
according to Student’s t test. CYP1A1 activity was measured by means of the rate of ethoxyresorufin O-
dealkylation, whereas CYP1A2 activity by means of the rate of methoxyresorufin-O-dealkylation as described
by Burke and colleagues [28]. Panel C: to visualize CYP1A2 on all lanes, we loaded the samples
(corresponding to the treatment with BP and BP+menadione) at 0.5 μg of total protein per well and the control
sample at 80 μg of total protein per well.
doi:10.1371/journal.pone.0155135.g002
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Molecular mechanisms of the suppression of BP-induced CYP1A
activity by menadione
To study the possible mechanism of menadione-mediated suppression of BP-induced CYP1A
activity in vivo, we assessed the protein and mRNA levels of these enzymes in the liver of the
rats by western blotting and quantitative PCR (qPCR)/RT-PCR. As expected, in the hepatic
microsomes of untreated (control) rats, the CYP1A1 protein was undetectable, whereas the
CYP1A2 protein was detectable. BP and menadione elevated the levels of the CYP1A1 and
CYP1A2 proteins (Fig 2E and [26]). In the liver of the rats treated with both BP and menadi-
one, the CYP1A protein levels were lower in comparison with the group receiving BP alone
(Fig 2E), but still much higher than in the liver of the untreated animals.
As expected [1, 2], BP administration led to a significant increase in CYP1A1 and CYP1A2
mRNA levels according to both qPCR (Fig 2F and 2G) and RT-PCR (S5 Fig and S1 Text). In
contrast to previous reports [26, 46], we observed only a statistically insignificant trend for an
increase in the level of mRNA of these genes in response to menadione, according to qPCR
(Fig 2F and 2G). In agreement with the data on enzymatic activities (Fig 2B and 2E) and west-
ern blotting results (Fig 2E), there was a reduction in mRNA levels of CYP1A1 and CYP1A2 in
the liver of the rats receiving both BP and menadione in comparison with the BP-treated ani-
mals. Combined administration of menadione and BP caused a 2.6-fold decrease in the
CYP1A1mRNA level (Fig 2F) and a 5.3-fold decrease in the CYP1A2mRNA level (Fig 2G) in
comparison with BP treatment. These data indicate that menadione-mediated inhibition of
BP-induced CYP1A in vivo takes place at the transcriptional level. It appears that the inhibitory
properties of menadione towards CYP1A1 enzymatic activity (Fig 1) may contribute to the
overall inhibitory effect but do not represent the primary mechanism of menadione-driven
downregulation of the BP-induced CYP1A1 activation in vivo.
Next, we analyzed mRNA levels of AhR, ARNT, and AhR repressor (AhRR) because the
quantities of these proteins are known to influence CYP1A expression [2, 47–49]. As shown in
Fig 3A and 3B, neither AhR nor ARNT were affected significantly by any of the treatments
tested in the present study. The mRNA level of AhRR (Fig 3C) was below the detection limit in
Fig 3. Menadione does not changemRNA expression of AhR and ARNT but reduces benzo(α)pyrene (BP)-induced AhRR expression.Menadione
does not influence the expression of genes AhR (panel A) and ARNT (panel B), but reduces the mRNA level of AhR repressor (AhRR) (panel C) that is
increased by BP. Rats received BP at 25 mg/(kg body weight) once a day for three days, menadione (15 mg/kg for four days), or both BP (25 mg/[kg body
weight] for three days) and menadione (15 mg/kg for four days). The control group received vegetable oil. The data are presented as mean ± SEM (n = 4 to
5); *p < 0.05 according to ANOVA with the Newman–Keuls post hoc test.
doi:10.1371/journal.pone.0155135.g003
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the liver of the untreated animals. BP administration robustly increased AhRR expression in
comparison with the untreated and menadione-treated animals. On the other hand, coadmin-
istration of menadione and BP was accompanied by a reduction in the AhRRmRNA level in
comparison with the group receiving BP alone. The above results suggest that the menadione-
driven inhibition of BP-induced CYP1A activation cannot be explained either by downregula-
tion of AhR/ARNT or by upregulation of AhRR expression.
We then tested functional activity of the AhR–ARNT complex by an EMSA. Treatment
with BP, but not menadione, increased DNA-binding activity of AhR in the nuclear extracts
from the rat liver (Fig 4A and 4B). Coadministration of menadione and BP caused a pro-
nounced decrease in the intensity of the bands corresponding to the 32P-labeled XRE3–AhR–
ARNT complex in comparison with the treatment with BP or menadione only. The dose-
dependent decrease of the intensity of the respective band in the presence of the 20-, 50-, or
75-fold excess of an unlabeled oligonucleotide is indicative of the specificity of the binding
(Fig 4A).
Because transcription factors Oct-1 and C/EBP are involved in negative regulation of
CYP1A [3, 4], we attempted to determine whether these transcription factors are involved in
the menadione-driven downregulation of BP-induced CYP1A activity. As shown in Fig 4C–4J,
no changes in DNA-binding activity of these proteins were observed in the liver of the experi-
mental animals in response to either menadione or BP (Fig 4C–4J). Coadministration of mena-
dione and BP increased the DNA-binding activity of Oct-1 (Fig 4E and 4F) and C/EBP (Fig 4I
and 4J) in comparison with the control group or group receiving BP treatment alone. Specific-
ity of the binding was confirmed by means of mutant oligonucleotides. Thus, it is likely that
menadione promotes binding of the proteins Oct-1 and C/EBP to the CYP1A promoter and
thereby downregulates the BP-induced CYP1A expression.
Our results indicate that menadione inhibits CYP1A1 activity in vitro by a noncompetitive
mechanism (Fig 1) and in vivo via suppression of CYP1A1 gene transcription (Fig 2F). The
downregulation of BP-induced CYP1A1mRNA is not caused by either upregulation of AhRR
or reduced expression of AhR and ARNT. Instead, it is mediated by a decrease in positive
input (binding of AhR to XRE) and an increase in negative input (binding of Oct-1 and C/EBP
to the CYP1A1 promoter region; Fig 5).
Discussion
Induction of CYP1A enzymes that occurs via the AhR signal transduction pathway has been
well characterized previously, but negative regulation of these enzymes is poorly understood.
Several studies showed that weak inducers of CYP1A can downregulate the activation of these
enzymes caused by a procarcinogenic PAH via different mechanisms [11–15, 26]. In our earlier
work [26], we demonstrated that menadione (a synthetic water-soluble analog of vitamin K3
commonly used as a therapeutic agent) is a “weak” CYP1A inducer.
In the present study, we showed that menadione can downregulate BP-induced expression
of AhR-dependent genes and addressed possible mechanisms of this effect. Because menadione
is known to inhibit activity of some CYPs in vitro [50], we first tested whether it can do the
same to CYP1A1. Menadione indeed inhibited CYP1A1 activity in rat hepatic microsomes via
a noncompetitive mechanism (Fig 1). In the present study, inhibition of CYP1A1 by menadi-
one in vitro was found to be weaker than inhibition by the other naturally occurring CYP1A1
inhibitors such as quercetin [51], piceatannol [52], trans-resveratrol [52], and indolo(3,2)car-
bazole [53]. Nevertheless, according to our previous research on tolerable doses of this sub-
stance [27], it seemed theoretically possible to attain a sufficient concentration of menadione
to achieve inhibition of BP-induced CYP1A1 activation in the rat liver.
Menadione Downregulates CYP1A In Vivo and In Vitro
PLOSONE | DOI:10.1371/journal.pone.0155135 May 11, 2016 10 / 17
Fig 4. Menadione changes DNA-binding activity of some nuclear proteins from the rat liver (AhR/ARNT, Oct-1, and C/EBP). (A, B) EMSA analysis of
binding of AhR/ARNT to XRE3, (C–F) Oct-1 to NRE, and (G–J) C/EBP to the C/EBP response element in the nuclear extracts from the liver of untreated rats
(control) and the rats treated with menadione (15 mg/kg for four days), benzo(α)pyrene (BP; 25 mg/kg), or both BP (25 mg/[kg body weight] for three days)
and menadione (15 mg/kg for four days). The specificity of the bands was confirmed by means of mutated oligonucleotides or an excess of an unlabeled
oligonucleotide. The density of the bands was measured in pixels using Totallab software. The data are presented as mean ± SEM (n = 3); *p < 0.05
according to ANOVA with the Newman–Keuls post hoc test.
doi:10.1371/journal.pone.0155135.g004
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We then proceeded to animal experiments and demonstrated that menadione indeed
reduces the BP-induced activity of CYP1A in the rat liver (Fig 2B and 2D). It should be noted
that in vivo, this effect is mediated neither by direct inhibition of enzymatic activities nor by
oxidative damage (S3 Fig); this finding is in agreement with our present results (Fig 1) and pre-
viously published data [54, 55]. In addition, this interference by menadione with the action of
BP is not caused by toxicity or liver damage because the liver function indicators ALT and AST
remained unchanged (S4B and S4C Fig). Our results indicate that in vivo, menadione downre-
gulates CYP1A genes via a reduction in their mRNA levels (Fig 2F and 2G). In contrast to pre-
viously published data [26], in the present study, we did not observe a statistically significant
increase in the CYP1A1mRNA level in response to menadione. This discrepancy can be
explained by the methodological differences between these studies. Previously, we collected
samples 20 h after the last administration of menadione, whereas in this study, 24 h after. Upre-
gulation of CYP1A1mRNA in response to an inducer may be transient, as shown for the aro-
matic hydrocarbon ethylbenzene [56]. In addition, menadione is rapidly excreted by kidneys
[57]. Thus, the combination of these two factors can result in bell-shaped upregulation of
CYP1A1mRNA in response to menadione; in 24 h, we might miss the peak of this
upregulation.
We hypothesized that downregulation of BP-induced CYP1A1 induction by menadione can
be caused by menadione’s influence on upstream regulatory proteins, because in addition to
CYP1A, this compound downregulates BP-induced activity of another xenobiotic-metaboliz-
ing enzyme (GST), which is at least partially regulated by AhR (S1 Fig).
Therefore, we first measured the expression levels of AhR, ARNT, and AhRR because they
were previously shown to modulate expression of AhR-dependent genes [58, 59]. None of the
treatments influenced expression of AhR and ARNT, but menadione suppressed the BP-
induced expression of AhRR. Downregulation of AhRR is not surprising because its expression
(same as expression of CYP1A) is controlled by an AhR-dependent signaling pathway [60, 61].
Although some weak inducers downregulate AhR signaling via AhRR [59], our data indicate
that menadione-driven suppression of the BP-induced CYP1A1 activation is not mediated by
AhRR.
Fig 5. Possiblemechanisms of the menadione-driven inhibition of the benzo(α)pyrene (BP)-induced
AhR-dependent signal transduction pathway.Menadione decreases DNA-binding activity of the AhR–
ARNT complex thus reducing positive input, and at the same time, activates Oct-1, which inhibits expression
of AhR-dependent genes. red triangle—Benzo(α)pyrene, green oval with brown, blue, yellow and red ovals
inside—inactive AhR in complex with its protein partners, green oval with a triangle inside—AhR activated by
benzo(α)pyrene, pink oval—ARNT, yellow circle—menadione, blue oval—mediator protein, turquoise–light
gray oval—Oct-1, NRE: negative regulatory element, XRE: xenobiotic-responsive element, AhR: aryl
hydrocarbon receptor, ARNT: aryl hydrocarbon receptor nuclear translocator.
doi:10.1371/journal.pone.0155135.g005
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Next, we tested functional activity of AhR using EMSA. As expected [62], BP increased
DNA-binding activity of AhR (Fig 4A and 4B). Menadione alone did not affect this activity,
but when menadione was coadministered with BP, it downregulated the BP-induced binding
of the AhR/ARNT heterodimer to the synthetic XRE. According to the literature, some weak
AhR ligands may compete with PAH for binding to the receptor and thus form AhR–ligand
complexes with a reduced ability to recruit basic transcription factors to the promoters of target
genes, thereby counteracting the effects of PAH on CYP1A [63, 64]. Nonetheless, this is an
unlikely mechanism behind the menadione-driven suppression of BP-induced activation of
AhR-dependent genes because according to the EMSA results (Fig 4A and 4B), menadione
itself fails to increase the functional activity of AhR. It should be noted that no other signal
transduction pathways except the one mediated by AhR have been previously shown to upre-
gulate CYP1A1. Our results (Figs 2 and 4) suggest that menadione increases CYP1A1 activity
independently of AhR, but additional studies are necessary to clarify this question.
Because the expression of CYP1A may be inhibited by transcription factors Oct-1 and C/
EBP [3, 4], we assessed the influence of menadione on functional activity of these proteins. We
demonstrated that in nuclear extracts from the liver of the rats treated with both BP and mena-
dione, DNA-binding activity of both Oct-1 and C/EBP was higher than that in the liver of the
rats receiving BP alone.
Our working model regarding the suppression of the BP-induced expression of AhR-depen-
dent genes by menadione is presented in Fig 5. Both reduction in positive regulation and
enhancement of negative regulation contribute to this effect. Menadione decreases the binding
of AhR/ARNT to XRE (as we saw in the nuclear extract from the liver of rats treated with BP
and menadione; Fig 4A and 4B). At the same time, menadione activates the Oct-1 protein that
binds to NRE in the promoter of AhR-responsive genes and downregulates their expression.
The menadione-driven inhibition of the BP-induced activities of AhR-responsive genes was
only partial (~40–60% reduction). Nevertheless, comparable or even weaker suppression of the
cell response to TCDD (measured using activity of CYP1A1 as a marker) by vitamin A was suffi-
cient to decrease the liver damage in the mice treated with TCDD, according to histological analy-
sis [15]. Taken together, these observations suggest that the menadione-driven suppression of BP-
induced AhR activation and the subsequent decrease in CYP1A1 activity may have physiological
and clinical significance. Many people are chronically exposed to PAHs in their lifetime because
these chemicals are present in exhaust fumes of internal-combustion engines, in emissions from
thermal power generators, and in tobacco smoke. Long-term exposure to PAH can lead to the
development of lymphohemopoietic and gastrointestinal neoplasms and breast and lung cancers
[65, 66]. Indeed, workers in the industries utilizing PAHs in technological processes—such as alu-
minum and coke production, iron and steel foundries, tar distillation, roofing, and road paving—
are at an increased risk of lung, skin, and bladder cancers [19]. It is generally accepted that the tox-
icity of these chemicals is mediated by AhR [19–22]. Therefore, nutritional substances such as
menadione that interfere with the action of PAHs by preventing/suppressing activation of AhR-
responsive genes (such as CYP1A) in vivomay prevent tumor formation and development.
Conclusions
Our results indicate that menadione suppresses BP-induced activity of AhR and transcription-
ally downregulates target genes of AhR in vivo. This effect is accompanied by a reduction in the
DNA-binding activity of the AhR/ARNT heterodimer and by enhancement of the binding of
Oct-1 and CEBP to the target promotor. Because of the important role of AhR and its target
genes in tumor formation, our results provide the basis for further studies of menadione in ani-
mal models of BP-induced cancer.
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Supporting Information
S1 Fig. Glutathione S-transferase activity. Administration of menadione or BP increases glu-
tathione S-transferase activity. Coadministration of BP and menadione attenuates the enhance-
ment of glutathione S-transferase activity by BP. The data are presented as mean ± SEM (n = 4
to 9); p< 0.05 according to ANOVA with the Newman–Keuls post hoc test.
(TIFF)
S2 Fig. NADPH cytochrome P450 reductase activity.Menadione, BP, or coadministration of
menadione and BP do not influence the NADPH cytochrome P450 reductase activity. The data
are presented as mean ± SEM (n = 4 to 16).
(TIFF)
S3 Fig. Malondialdehyde level.Menadione, BP, or coadministration of menadione and BP do
not influence the malondialdehyde level in the liver of the experimental animals. The data are
presented as mean ± SEM (n = 4 to 6).
(TIFF)
S4 Fig. Body weight of the rats and transaminase activities.Menadione (15 mg/kg for 4
days), BP (25 mg/kg for 3 days), or menadione+BP do not change body weight of the rats.
Menadione changes the ALT (A) and AST (B) activities in the serum of rats. In rats treated
with BP, the ALT levels were lower in comparison with the group receiving menadione or BP+-
menadione. In the liver of the rats treated with either BP or both BP and menadione, the AST
levels were higher than in the liver of untreated animals. The data are presented as
mean ± SEM (n = 4 to 5); p< 0.05 according to ANOVA with the Newman–Keuls post hoc
test.
(TIFF)
S5 Fig. CYP1A1, CYP1A1, AhR, ARNT and AhRRmRNA levels measured by RT-PCR (A,
B) Coadministration of BP and menadione suppresses mRNA expression that was induced by
BP. (C) Menadione does not influence the expression of the genes AhR and (D) ARNT but (E)
reduces the mRNA level of AhR repressor (AhRR) that is increased by BP. Rats received BP at
25 mg/(kg body weight) once a day for three days, or both BP (25 mg/[kg body weight] for
three days) and menadione (15 mg/kg for four days). The data are presented as mean ± SEM
(n = 4 to 5); p< 0.05 according to ANOVA with the Newman–Keuls post hoc test, #p< 0.05
according to Student’s t test.
(TIFF)
S1 Text. The RT-PCR protocol.
(DOCX)
Author Contributions
Conceived and designed the experiments: YAS AYG. Performed the experiments: YAS MLP
ENP. Analyzed the data: YAS MLP ENP ALM VVL AYG. Contributed reagents/materials/
analysis tools: ALM AYG VVL. Wrote the paper: YAS MLP ENP ALM VVL AYG.
References
1. Whitlock JP. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol. 1999; 39:103–25. doi:
10.1146/annurev.pharmtox.39.1.103 PMID: 10331078.
2. MaQ. Induction of CYP1A1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding
biological roles. Curr Drug Metab. 2001; 2(2):149–64. PMID: 11469723.
Menadione Downregulates CYP1A In Vivo and In Vitro
PLOSONE | DOI:10.1371/journal.pone.0155135 May 11, 2016 14 / 17
3. Bhat R, Weaver JA, Sterling KM, Bresnick E. Nuclear transcription factor Oct-1 binds to the 5'-upstream
region of CYP1A1 and negatively regulates its expression. Int J Biochem Cell Biol. 1996; 28(2):217–27.
PMID: 8729008.
4. Cho IJ, Kim SG. Oltipraz inhibits 3-methylcholanthrene induction of CYP1A1 by CCAAT/enhancer-
binding protein activation. J Biol Chem. 2003; 278(45):44103–12. doi: 10.1074/jbc.M307597200 PMID:
12941938.
5. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH. The aryl hydrocarbon receptor complex
and the control of gene expression. Crit Rev Eukaryot Gene Expr. 2008; 18(3):207–50. PMID:
18540824; PubMed Central PMCID: PMCPMC2583464.
6. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous
and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003; 43:309–34. doi: 10.1146/annurev.
pharmtox.43.100901.135828 PMID: 12540743.
7. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor.
Chem Res Toxicol. 2008; 21(1):102–16. doi: 10.1021/tx7001965 PMID: 18076143; PubMed Central
PMCID: PMCPMC2572005.
8. Gambone CJ, Hutcheson JM, Gabriel JL, Beard RL, Chandraratna RA, Soprano KJ, et al. Unique prop-
erty of some synthetic retinoids: activation of the aryl hydrocarbon receptor pathway. Mol Pharmacol.
2002; 61(2):334–42. PMID: 11809858.
9. Lemaire G, Delescluse C, Pralavorio M, Ledirac N, Lesca P, Rahmani R. The role of protein tyrosine
kinases in CYP1A1 induction by omeprazole and thiabendazole in rat hepatocytes. Life Sci. 2004; 74
(18):2265–78. doi: 10.1016/j.lfs.2003.09.056 PMID: 14987951.
10. Mohammadi-Bardbori A, Bengtsson J, Rannug U, Rannug A, Wincent E. Quercetin, resveratrol, and
curcumin are indirect activators of the aryl hydrocarbon receptor (AHR). Chem Res Toxicol. 2012; 25
(9):1878–84. doi: 10.1021/tx300169e PMID: 22867086.
11. Kang ZC, Tsai SJ, Lee H. Quercetin inhibits benzo[a]pyrene-induced DNA adducts in human Hep G2
cells by altering cytochrome P-450 1A1 gene expression. Nutr Cancer. 1999; 35(2):175–9. doi: 10.
1207/S15327914NC352_12 PMID: 10693172.
12. Wen X, Walle UK, Walle T. 5,7-Dimethoxyflavone downregulates CYP1A1 expression and benzo[a]
pyrene-induced DNA binding in Hep G2 cells. Carcinogenesis. 2005; 26(4):803–9. doi: 10.1093/carcin/
bgi015 PMID: 15661813.
13. Fukuda I, Sakane I, Yabushita Y, Sawamura S, Kanazawa K, Ashida H. Black tea theaflavins suppress
dioxin-induced transformation of the aryl hydrocarbon receptor. Biosci Biotechnol Biochem. 2005; 69
(5):883–90. PMID: 15914905.
14. Ciolino HP, Daschner PJ, Wang TT, Yeh GC. Effect of curcumin on the aryl hydrocarbon receptor and
cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol. 1998; 56(2):197–
206. PMID: 9698073.
15. Yang YM, Huang DY, Liu GF, Zhong JC, Du K, Li YF, et al. Inhibitory effects of vitamin A on TCDD-
induced cytochrome P-450 1A1 enzyme activity and expression. Toxicol Sci. 2005; 85(1):727–34. doi:
10.1093/toxsci/kfi130 PMID: 15728703.
16. Sidorova YA, Grishanova AY. Inhibitory effect of alpha-tocopherol on benzo(a)pyrene-induced CYPA1
activity in rat liver. Bull Exp Biol Med. 2005; 140(5):517–20. PMID: 16758613.
17. Mukai R, Shirai Y, Saito N, Fukuda I, Nishiumi S, Yoshida K, et al. Suppression mechanisms of flavo-
noids on aryl hydrocarbon receptor-mediated signal transduction. Arch Biochem Biophys. 2010; 501
(1):134–41. doi: 10.1016/j.abb.2010.05.002 PMID: 20450880.
18. Denison MS, Soshilov AA, He G, DeGroot DE, Zhao B. Exactly the same but different: promiscuity and
diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci.
2011; 124(1):1–22. doi: 10.1093/toxsci/kfr218 PMID: 21908767; PubMed Central PMCID:
PMC3196658.
19. Boffetta P, Jourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure
to polycyclic aromatic hydrocarbons. Cancer Causes Control. 1997; 8(3):444–72. PMID: 9498904.
20. Billiard SM, Timme-Laragy AR, Wassenberg DM, Cockman C, Di Giulio RT. The role of the aryl hydro-
carbon receptor pathway in mediating synergistic developmental toxicity of polycyclic aromatic hydro-
carbons to zebrafish. Toxicol Sci. 2006; 92(2):526–36. doi: 10.1093/toxsci/kfl011 PMID: 16687390.
21. Sagredo C, Mollerup S, Cole KJ, Phillips DH, Uppstad H, Ovrebo S. Biotransformation of benzo[a]pyr-
ene in Ahr knockout mice is dependent on time and route of exposure. Chem Res Toxicol. 2009; 22
(3):584–91. doi: 10.1021/tx8003664 PMID: 19216581.
22. Uno S, Dalton TP, Shertzer HG, Genter MB, Warshawsky D, Talaska G, et al. Benzo[a]pyrene-induced
toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA
Menadione Downregulates CYP1A In Vivo and In Vitro
PLOSONE | DOI:10.1371/journal.pone.0155135 May 11, 2016 15 / 17
adduct levels. Biochem Biophys Res Commun. 2001; 289(5):1049–56. doi: 10.1006/bbrc.2001.6110
PMID: 11741297.
23. Ghosh A, Ghosh D, Sarkar S, Mandal AK, Thakur Choudhury S, Das N. Anticarcinogenic activity of
nanoencapsulated quercetin in combating diethylnitrosamine-induced hepatocarcinoma in rats. Euro-
pean journal of cancer prevention: the official journal of the European Cancer Prevention Organisation.
2012; 21(1):32–41. doi: 10.1097/CEJ.0b013e32834a7e2b PMID: 21968689.
24. Piper JT, Singhal SS, Salameh MS, Torman RT, Awasthi YC, Awasthi S. Mechanisms of anticarcino-
genic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat
liver. Int J Biochem Cell Biol. 1998; 30(4):445–56. PMID: 9675878.
25. Kensler TW, Qian GS, Chen JG, Groopman JD. Translational strategies for cancer prevention in liver.
Nat Rev Cancer. 2003; 3(5):321–9. doi: 10.1038/nrc1076 PMID: 12724730.
26. Sidorova YA, Grishanova AY, Lyakhovich VV. Rat hepatic CYP1A1 and CYP1A2 induction by menadi-
one. Toxicol Lett. 2005; 155(2):253–8. doi: 10.1016/j.toxlet.2004.10.001 PMID: 15603920.
27. Sidorova YA, Grishanova AY. Dose- and time-dependent effects of menadione on enzymes of xenobi-
otic metabolism in rat liver. Bull Exp Biol Med. 2004; 137(3):231–4. PMID: 15232626.
28. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT. Ethoxy-, pentoxy- and ben-
zyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced
cytochromes P-450. Biochem Pharmacol. 1985; 34(18):3337–45. PMID: 3929792.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J
Biol Chem. 1951; 193(1):265–75. PMID: 14907713.
30. Phillips AH, Langdon RG. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation,
characterization, and kinetic studies. J Biol Chem. 1962; 237:2652–60. PMID: 14486217.
31. Habig WH, Pabst MJ, JakobyWB. Glutathione S-transferases. The first enzymatic step in mercapturic
acid formation. J Biol Chem. 1974; 249(22):7130–9. PMID: 4436300.
32. Andreeva LI, Kozhemiakin LA, Kishkun AA. [Modification of the method of determining lipid peroxida-
tion in a test using thiobarbituric acid]. Lab Delo. 1988;(11: ):41–3. PMID: 2463416.
33. Markovets AM, Saprunova VB, Zhdankina AA, Fursova AZh, Bakeeva LE, Kolosova NG. Alterations of
retinal pigment epithelium cause AMD-like retinopathy in senescence-accelerated OXYS rats. Aging
(Albany NY). 2011; 3(1):44–54. PMID: 21191149; PubMed Central PMCID: PMCPMC3047138.
34. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nature protocols.
2006; 1(3):1559–82. doi: 10.1038/nprot.2006.236 PMID: 17406449.
35. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature. 1970; 227(5259):680–5. PMID: 5432063.
36. Grishanova A, Yu, Lyakhovich VV. Using of antibodies to cytochrome P-450 library in xenobioticmeta-
bolism studies. In: Archakov A, Bachmanova G, editors. Cytochrome P-450: biochemistry and biophys-
ics. Moscow: INCOTNC; 1992. p. 525–7.
37. Gorski K, Carneiro M, Schibler U. Tissue-specific in vitro transcription from the mouse albumin pro-
moter. Cell. 1986; 47(5):767–76. PMID: 3779841.
38. Shapiro DJ, Sharp PA, Wahli WW, Keller MJ. A high-efficiency HeLa cell nuclear transcription extract.
DNA. 1988; 7(1):47–55. PMID: 3349904.
39. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utiliz-
ing the principle of protein-dye binding. Analytical biochemistry. 1976; 72:248–54. PMID: 942051.
40. Denison MS, Deal RM. The binding of transformed aromatic hydrocarbon (Ah) receptor to its DNA rec-
ognition site is not affected by metal depletion. Mol Cell Endocrinol. 1990; 69(1):51–7. PMID: 2157617.
41. Wang H, Qu X, De Plaen IG, HsuehW. Platelet-activating factor and endotoxin activate CCAAT/
enhancer binding protein in rat small intestine. British journal of pharmacology. 2001; 133(5):713–21.
doi: 10.1038/sj.bjp.0704102 PMID: 11429396; PubMed Central PMCID: PMC1572822.
42. Malone CS, Kuraishy AI, Fike FM, Loya RG, Mikkili MR, Teitell MA, et al. B29 gene silencing in pituitary
cells is regulated by its 3' enhancer. Journal of molecular biology. 2006; 362(2):173–83. doi: 10.1016/j.
jmb.2006.07.046 PMID: 16920149; PubMed Central PMCID: PMC2104784.
43. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor, N.Y.:
Cold Spring Harbor Laboratory; 1982.
44. Webb JL. Enzyme and metabolic inhibitors. New York,: Academic Press; 1963. v. <1–3 > p.
45. Gharavi N, El-Kadi AO. Down-regulation of aryl hydrocarbon receptor-regulated genes by tumor necro-
sis factor-alpha and lipopolysaccharide in murine hepatoma Hepa 1c1c7 cells. Journal of pharmaceuti-
cal sciences. 2005; 94(3):493–506. doi: 10.1002/jps.20267 PMID: 15627257.
Menadione Downregulates CYP1A In Vivo and In Vitro
PLOSONE | DOI:10.1371/journal.pone.0155135 May 11, 2016 16 / 17
46. Inouye K, Mae T, Kondo S, Ohkawa H. Inhibitory effects of vitamin A and vitamin K on rat cytochrome
P4501A1-dependent monooxygenase activity. Biochem Biophys Res Commun. 1999; 262(2):565–9.
doi: 10.1006/bbrc.1999.1240 PMID: 10462515.
47. Harper PA, Riddick DS, Okey AB. Regulating the regulator: factors that control levels and activity of the
aryl hydrocarbon receptor. Biochem Pharmacol. 2006; 72(3):267–79. doi: 10.1016/j.bcp.2006.01.007
PMID: 16488401.
48. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction
of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem. 2004; 279(23):23847–50. doi:
10.1074/jbc.R400004200 PMID: 15028720.
49. Ito S, Chen C, Satoh J, Yim S, Gonzalez FJ. Dietary phytochemicals regulate whole-body CYP1A1
expression through an arylhydrocarbon receptor nuclear translocator-dependent system in gut. J Clin
Invest. 2007; 117(7):1940–50. doi: 10.1172/JCI31647 PMID: 17607366; PubMed Central PMCID:
PMC1890999.
50. Floreani M, Carpenedo F. Inhibition of rat liver monooxygenase activities by 2-methyl-1,4-naphthoqui-
none (menadione). Toxicol Appl Pharmacol. 1990; 105(2):333–9. PMID: 2219123.
51. Sousa RL, Marletta MA. Inhibition of cytochrome P-450 activity in rat liver microsomes by the naturally
occurring flavonoid, quercetin. Arch Biochem Biophys. 1985; 240(1):345–57. PMID: 3925883.
52. Chang TK, Chen J, Yu CT. In vitro inhibition of rat CYP1A1 and CYP1A2 by piceatannol, a hydroxylated
metabolite of trans-resveratrol. Drug Metab Lett. 2007; 1(1):13–6. PMID: 19356012.
53. Chen YH, Riby J, Srivastava P, Bartholomew J, Denison M, Bjeldanes L. Regulation of CYP1A1 by
indolo[3,2-b]carbazole in murine hepatoma cells. J Biol Chem. 1995; 270(38):22548–55. PMID:
7673247.
54. Korashy HM, El-Kadi AO. Modulation of TCDD-mediated induction of cytochrome P450 1A1 by mer-
cury, lead, and copper in human HepG2 cell line. Toxicol In Vitro. 2008; 22(1):154–8. doi: 10.1016/j.tiv.
2007.08.003 PMID: 17889500.
55. Kim IS, Sohn HY, Jin I. Adaptive stress response to menadione-induced oxidative stress in Saccharo-
myces cerevisiae KNU5377. J Microbiol. 2011; 49(5):816–23. doi: 10.1007/s12275-011-1154-6 PMID:
22068500.
56. YuanW, Sequeira DJ, Cawley GF, Eyer CS, BackesWL. Time course for the modulation of hepatic
cytochrome P450 after administration of ethylbenzene and its correlation with toluene metabolism.
Arch Biochem Biophys. 1997; 339(1):55–63. doi: 10.1006/abbi.1996.9818 PMID: 9056233.
57. DeLuca HF. The Fat-soluble vitamins. New York: Plenum Press; 1978. xii, 287 p. p.
58. Chang CY, Puga A. Constitutive activation of the aromatic hydrocarbon receptor. Mol Cell Biol. 1998;
18(1):525–35. PMID: 9418899; PubMed Central PMCID: PMC121520.
59. Niestroy J, Barbara A, Herbst K, Rode S, van Liempt M, Roos PH. Single and concerted effects of
benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line
Caco-2. Toxicol In Vitro. 2011; 25(3):671–83. doi: 10.1016/j.tiv.2011.01.008 PMID: 21256954.
60. Karchner SI, Franks DG, Powell WH, Hahn ME. Regulatory interactions among three members of the
vertebrate aryl hydrocarbon receptor family: AHR repressor, AHR1, and AHR2. J Biol Chem. 2002; 277
(9):6949–59. doi: 10.1074/jbc.M110779200 PMID: 11742002.
61. Zudaire E, Cuesta N, Murty V, Woodson K, Adams L, Gonzalez N, et al. The aryl hydrocarbon receptor
repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest. 2008; 118
(2):640–50. doi: 10.1172/JCI30024 PMID: 18172554; PubMed Central PMCID: PMCPMC2157559.
62. Backlund M, Johansson I, Mkrtchian S, Ingelman-Sundberg M. Signal transduction-mediated activation
of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells. J Biol Chem. 1997; 272(50):31755–63.
PMID: 9395520.
63. Hestermann EV, Brown M. Agonist and chemopreventative ligands induce differential transcriptional
cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol. 2003; 23(21):7920–5. PMID:
14560034; PubMed Central PMCID: PMCPMC207605.
64. Backlund M, Ingelman-Sundberg M. Different structural requirements of the ligand binding domain of
the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. Mol Phar-
macol. 2004; 65(2):416–25. doi: 10.1124/mol.65.2.416 PMID: 14742684.
65. Marinković N, Pašalić D, Ferenčak G, Gršković B, Stavljenić Rukavina A. Dioxins and human toxicity.
Arh Hig Rada Toksikol. 2010; 61(4):445–53. doi: 10.2478/10004-1254-61-2010-2024 PMID:
21183436.
66. Céspedes MA, Galindo MI, Couso JP. Dioxin toxicity in vivo results from an increase in the dioxin-inde-
pendent transcriptional activity of the aryl hydrocarbon receptor. PLoS One. 2010; 5(11):e15382. doi:
10.1371/journal.pone.0015382 PMID: 21079739; PubMed Central PMCID: PMCPMC2975661.
Menadione Downregulates CYP1A In Vivo and In Vitro
PLOSONE | DOI:10.1371/journal.pone.0155135 May 11, 2016 17 / 17
